Jan 22, 2019 Acorda Therapeutics, Inc. (NASDAQ:ACOR) Announces Publication Of Third Phase Results ... Acorda Therapeutics, Inc. (NASDAQ:ACOR) Announces Publication Of Third Phase Results …The results announced in the Lancet Neurology are positive and support the potential of using INBRIJA™ as a treatment alternative. Levodopa is in ... read morePublished on 2019-01-22